Palavras-chave
Multirresistência
Infecção
Sistema nervoso central
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar os padrões de resistência, os desafios clínicos e as possibilidades de tratamento nas infecções do sistema nervoso central (SNC) causadas por Acinetobacter baumannii multirresistente. Revisão bibliográfica: As infecções por Acinetobacter baumannii multirresistentes presentes no SNC têm sido um grande desafio clínico, principalmente quando associadas a neurocirurgia ou traumatismo cranioencefálico. O tratamento atual para infecções do SNC causadas por A. baumannii multirresistente consiste na administração endovenosa combinada de agentes como: carbapenêmicos com ampicilina/sulbactam; carbapenêmicos associado à colistina; colistina com rifampicina e sulbactam; e tigeciclina associada à rifampicina e à ampicilina. Porém, devido à baixa permeabilidade desses agentes na barreira hematoencefálica, o uso de terapia antimicrobiana intratecal deve ser considerada e os principais agentes são: colistina, tigeciclina, gentamicina, amicacina e polimixina B. Considerações finais: O A. baumannii se tornou um dos patógenos mais desafiadores adquiridos em ambientes hospitalares. A dificuldade para penetração dos antimicrobianos na barreira hematoencefálica somada aos mecanismos de resistência desse microrganismo aos antimicrobianos dificultam o controle infeccioso, logo, favorecem uma alta taxa de mortalidade nas meningoencefalites. É essencial detectá-lo precocemente e adotar procedimentos rigorosos de controle de infecção. Ensaios clínicos são necessários para melhor assegurar a melhor escolha antimicrobiana e tempo de tratamento.
Referências
DENG ZW, et al. A case report of intraventricular and intrathecal tigecycline infusions for an extensively drug-resistant intracranial Acinetobacter baumannii infection. Medicine, 2019; 98(15): 1-5.
GAUTAM D, et al. Acinetobacter baumannii: An overview of emerging multidrug-resistant pathogen. Medical Journal Of Malaysia, 2022; 77(3): 357-371.
GUO S, et al. Analysis of tigecycline in cerebrospinal fluid and serum of patients with multidrug-resistant Acinetobacter baumannii central nervous system infection by HPLC-MS/MS. Authorea, 2023; 1: 1-9.
HUANG G, et al. Two Cases Report of Intrathecal Tigecycline Therapy for Intracranial Infection with Acinetobacter baumannii and Review of Literatures. Infection And Drug Resistance, 2022; 15: 2211-2217.
KANAFANI Z, et al. Acinetobacter infection: Epidemiology, microbiology, pathogenesis, clinical features, and diagnosis. Uptodate, 2022; 1: 1-12.
KANAFANI Z, et al. Acinetobacter infection: Treatment and prevention. Uptodate, 2023; 1: 1-27.
LI H, et al. Outcome of Using Intraventricular Plus Intravenous Polymyxin B in Post-neurosurgical Patients With Multi/Extensively Drug-Resistant Gram-Negative Bacteria-Induced Intracranial Infection. Frontiers In Medicine, 2022; 9: 1-7.
LI LM, et al. Spinal arachnoiditis followed by intrathecal tigecycline therapy for central nervous system infection by extremely drug-resistant Acinetobacter baumannii. Journal Of International Medical Research, 2020; 48(7): 1-5.
LIU D, et al. Treatment of Carbapenem-Resistant Multidrug-Resistant Gram-Negative Bacilli with Intracerebroventricular Injection of Polymyxin B: a retrospective study. Infection And Drug Resistance, 2022; 15: 7653-7666.
MIZRAHI CJ, et al. Combination Treatment with Intravenous Tigecycline and intraventricular and Intravenous Colistin in Postoperative Ventriculitis Caused by Multidrug-resistant Acinetobacter baumannii. Cureus, 2019; 11(1): 1-6.
MURRAY G, et al. Acinetobacter baumannii: evolution of antimicrobial resistance: treatment options. Seminars In Respiratory And Critical Care Medicine, 2015; 36(01): 85-98.
OPAL SM, POP-VICAS A. Acinetobacter Species. Principles and Practice of Infectious Diseases. Eighth edition. Philadelphia: J. Bennett, 2015; p. 235-251.
PANDEY S, et al. Outcome Following the Treatment of Ventriculitis Caused by Multi/Extensive Drug Resistance Gram Negative Bacilli; Acinetobacter baumannii and Klebsiella pneumoniae. Frontiers In Neurology, 2019; 9: 1-8.
PAN S, et al. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinetobacter baumannii: a retrospective cohort study. Antimicrobial Resistance & Infection Control, 2018; 7(1): 1-9.
PHILLIPS M. Acinetobacter Species. Principles and Practice of Infectious Diseases. Eighth edition.
PHILADELPHIA: J. Bennett, 2015; p. 2552-2558.
QUEIROZ YM, et al. Mecanismo de resistência da bactéria Acinetobacter Baumannii e suas implicações no controle das infecções hospitalares. Revista Brasileira de Análises Clínicas, 2022; 54(1): 37-43.
SARI ND, et al. Evaluation of Intraventricular/Intrathecal Antimicrobial Therapy in the Treatment of Nosocomial Meningitis Caused by Multidrug-Resistant Gram-Negative Bacteria after Central Nervous System Surgery. Canadian Journal Of Infectious Diseases And Medical Microbiology, 2021; 2021: 1-6.
TIAN Y, et al. Detection of multidrug-resistant Acinetobacter baumannii by metagenomic next-generation sequencing in central nervous system infection after neurosurgery: a case report. Frontiers In Public Health, 2022; 10: 1-7.
TU Q, et al. Acinetobacter Baumannii Phages: past, present and future. Viruses, 2023; 15(3): 673-700.
YANG X, et al. Treatment of Central Nervous System Infection Caused by Multidrug-Resistant Acinetobacter baumannii with Intravenous and Intraventricular Colistin Sulfate: a case report and literature review. Infection And Drug Resistance, 2023; 16: 6029-6038.
ZHONG L, et al. Sequential intraventricular injection of tigecycline and polymyxin B in the treatment of intracranial Acinetobacter baumannii infection after trauma: a case report and review of the literature. Military Medical Research, 2020; 7(1): 1-6.